Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 9/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858417 | 0.84 | ILK (0.51) | UBE2MDCUN1D1ALDH1A1GAAGFER | |
| SCHEMBL17859473 | 0.77 | SMN1; SMN2 (0.53) | POLBALDH1A1GAANPC1RAB9A | |
| SCHEMBL20571232 | 0.77 | HCRTR1 (0.43) | NPC1 | |
| SCHEMBL23539202 | 0.76 | UBE2M (0.44) | UBE2MDCUN1D1POLBALDH1A1GAA | |
| SCHEMBL25113833 | 0.74 | LMNA (0.56) | UBE2MDCUN1D1POLBALDH1A1GAA | |
| SCHEMBL24251903 | 0.73 | NPC1 (0.40) | UBE2MDCUN1D1POLBALDH1A1GAA | |
| SCHEMBL30082324 | 0.73 | NPC1 (0.40) | UBE2MDCUN1D1POLBALDH1A1GAA | |
| SCHEMBL20569824 | 0.72 | UBE2M (0.38) | UBE2MDCUN1D1POLBALDH1A1GAA | |
| SCHEMBL20570881 | 0.72 | CYP11B1 (0.39) | UBE2MDCUN1D1ALDH1A1GAAGFER | |
| SCHEMBL25877964 | 0.72 | UBE2M (0.39) | UBE2MDCUN1D1POLBGAAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180362502-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218044-A2 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS INC (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | UBE2M 4753/4885DCUN1D1 3066/4885POLB 4580/4885 |
| US-20180362502-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | UBE2M 4753/4885DCUN1D1 3066/4885POLB 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.